Another finding proved that targeting VCP with EerI in non-small cell lung carcinoma (NSCLC) restored p53 and NFB levels and ameliorated the growth and tumorigenicity, improving clinical outcomes [27]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.